Hepatotoxins Stocks List
|CPIX||F||Cumberland Pharmaceuticals Inc.||-1.64|
|GILD||C||Gilead Sciences, Inc.||1.67|
|PLXP||B||PLx Pharma Inc.||-1.12|
|PRTK||B||Paratek Pharmaceuticals, Inc.||-1.35|
|HEPA||F||Hepion Pharmaceuticals, Inc.||-0.60|
|ATXI||F||Avenue Therapeutics, Inc.||-2.37|
|DWSH||F||AdvisorShares Dorsey Wright Short ETF||37.4|
|BIS||D||ProShares UltraShort Nasdaq Biotechnology||8.7|
|IBB||D||iShares Nasdaq Biotechnology Index Fund||7.83|
|VIRS||A||Pacer BioThreat Strategy ETF||7.15|
|BIB||D||ProShares Ultra Nasdaq Biotechnology||5.92|
View all Hepatotoxins related ETFs...
|2021-04-16||ATXI||Lower Bollinger Band Walk||Weakness|
|2021-04-16||ATXI||Calm After Storm||Range Contraction|
|2021-04-16||ATXI||Lizard Bullish||Bullish Day Trade Setup|
|2021-04-16||CPIX||Narrow Range Bar||Range Contraction|
|2021-04-16||CPIX||Stochastic Reached Oversold||Weakness|
|2021-04-16||GILD||Pocket Pivot||Bullish Swing Setup|
|2021-04-16||GILD||MACD Bullish Signal Line Cross||Bullish|
|2021-04-16||HEPA||Stochastic Buy Signal||Bullish|
|2021-04-16||PLXP||Upper Bollinger Band Walk||Strength|
|2021-04-16||PRFX||Lower Bollinger Band Walk||Weakness|
|2021-04-16||PRFX||New 52 Week Low||Weakness|
|2021-04-16||PRFX||New 52 Week Closing Low||Bearish|
|2021-04-16||PRTK||Upper Bollinger Band Walk||Strength|
|2021-04-16||PRTK||Calm After Storm||Range Contraction|
|2021-04-16||PRTK||Cup with Handle||Other|
|2021-04-16||SNY||Stochastic Reached Overbought||Strength|
Hepatotoxicity (from hepatic toxicity) implies chemical-driven liver damage. Drug-induced liver injury is a cause of acute and chronic liver disease.
The liver plays a central role in transforming and clearing chemicals and is susceptible to the toxicity from these agents. Certain medicinal agents, when taken in overdoses and sometimes even when introduced within therapeutic ranges, may injure the organ. Other chemical agents, such as those used in laboratories and industries, natural chemicals (e.g., microcystins) and herbal remedies can also induce hepatotoxicity. Chemicals that cause liver injury are called hepatotoxins.
More than 900 drugs have been implicated in causing liver injury (see LiverTox, external link, below) and it is the most common reason for a drug to be withdrawn from the market. Hepatotoxicity and drug-induced liver injury also account for a substantial number of compound failures, highlighting the need for toxicity prediction models (e.g. DTI), and drug screening assays, such as stem cell-derived hepatocyte-like cells, that are capable of detecting toxicity early in the drug development process. Chemicals often cause subclinical injury to the liver, which manifests only as abnormal liver enzyme tests.
Drug-induced liver injury is responsible for 5% of all hospital admissions and 50% of all acute liver failures.